25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Inoviq Ltd
Buy, Hold or Sell?

Let's analyze Inoviq together

I guess you are interested in Inoviq Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Inoviq Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Inoviq Ltd

I send you an email if I find something interesting about Inoviq Ltd.

1. Quick Overview

1.1. Quick analysis of Inoviq (30 sec.)










1.2. What can you expect buying and holding a share of Inoviq? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.18
Expected worth in 1 year
A$0.18
How sure are you?
31.3%

+ What do you gain per year?

Total Gains per Share
A$0.00
Return On Investment
0.7%

For what price can you sell your share?

Current Price per Share
A$0.45
Expected price per share
A$0.46 - A$0.465
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Inoviq (5 min.)




Live pricePrice per Share (EOD)
A$0.45
Intrinsic Value Per Share
A$-0.25 - A$-0.26
Total Value Per Share
A$-0.07 - A$-0.08

2.2. Growth of Inoviq (5 min.)




Is Inoviq growing?

Current yearPrevious yearGrowGrow %
How rich?$13.1m$13.9m-$1.9m-15.7%

How much money is Inoviq making?

Current yearPrevious yearGrowGrow %
Making money-$1.3m-$2.2m$878.5k65.7%
Net Profit Margin-915.2%-2,121.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Inoviq (5 min.)




2.4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  


Richest
#95 / 136

Most Revenue
#126 / 136

Most Profit
#68 / 136

Most Efficient
#127 / 136
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Inoviq?

Welcome investor! Inoviq's management wants to use your money to grow the business. In return you get a share of Inoviq.

First you should know what it really means to hold a share of Inoviq. And how you can make/lose money.

Speculation

The Price per Share of Inoviq is A$0.45. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Inoviq.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Inoviq, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.18. Based on the TTM, the Book Value Change Per Share is A$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Inoviq.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.01-2.2%-0.01-2.7%-0.01-2.9%-0.02-4.3%-0.01-3.0%
Usd Book Value Change Per Share0.000.0%0.000.1%-0.01-2.8%0.000.8%0.000.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%0.000.1%-0.01-2.8%0.000.8%0.000.8%
Usd Price Per Share0.37-0.39-0.42-0.49-0.31-
Price to Earnings Ratio-9.11--8.74--8.50--7.47--5.03-
Price-to-Total Gains Ratio-0.38-10,533,096.18-2,106,587.06-1,316,605.16-
Price to Book Ratio3.12-3.67-3.35-3.15-2.92-
Price-to-Total Gains Ratio-0.38-10,533,096.18-2,106,587.06-1,316,605.16-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.29637
Number of shares3374
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (3374 shares)1.8512.80
Gains per Year (3374 shares)7.3951.21
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
107-305141
20154010292
3022110154143
4030180205194
5037250256245
6044320307296
7052390358347
8059460410398
9067530461449
10074600512500

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.032.00.00.0%0.032.00.00.0%
Book Value Change Per Share1.01.02.025.0%3.05.04.025.0%5.010.05.025.0%10.014.08.031.3%10.014.08.031.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.032.00.0%0.00.032.00.0%
Total Gains per Share1.01.02.025.0%3.05.04.025.0%5.010.05.025.0%10.014.08.031.3%10.014.08.031.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Inoviq Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.001-100%-0.0190%0.006-100%0.006-100%
Book Value Per Share--0.1790.165+9%0.191-6%0.214-16%0.142+26%
Current Ratio--7.0746.009+18%5.738+23%8.513-17%7.920-11%
Debt To Asset Ratio--0.0790.085-7%0.103-23%0.090-12%0.149-47%
Debt To Equity Ratio--0.0860.093-7%0.116-26%0.100-14%0.241-64%
Dividend Per Share----0%-0%-0%-0%
Eps---0.015-0.018+18%-0.020+31%-0.030+93%-0.020+32%
Free Cash Flow Per Share---0.013-0.012-5%-0.025+95%-0.017+33%-0.012-4%
Free Cash Flow To Equity Per Share--0.0150.001+1189%-0.025+275%-0.001+107%0.001+2269%
Gross Profit Margin--1.0341.055-2%1.073-4%1.159-11%1.265-18%
Intrinsic Value_10Y_max---0.262--------
Intrinsic Value_10Y_min---0.246--------
Intrinsic Value_1Y_max---0.070--------
Intrinsic Value_1Y_min---0.069--------
Intrinsic Value_3Y_max---0.178--------
Intrinsic Value_3Y_min---0.170--------
Intrinsic Value_5Y_max---0.245--------
Intrinsic Value_5Y_min---0.230--------
Market Cap50187150.000-24%62455120.00066776791.250-6%70401418.750-11%82200975.350-24%52184180.344+20%
Net Profit Margin---2.513-9.152+264%-21.219+744%-20.110+700%-26.009+935%
Operating Margin---2.591-7.501+189%-15.756+508%-15.090+482%-22.585+772%
Operating Ratio--5.20212.010-57%24.407-79%20.676-75%26.830-81%
Pb Ratio2.511-24%3.1253.672-15%3.351-7%3.151-1%2.921+7%
Pe Ratio-7.323+20%-9.113-8.738-4%-8.504-7%-7.470-18%-5.030-45%
Price Per Share0.450-24%0.5600.599-6%0.631-11%0.737-24%0.468+20%
Price To Free Cash Flow Ratio-8.903+20%-11.079-13.237+19%-6.824-38%-12.861+16%-8.455-24%
Quick Ratio--6.8465.577+23%5.358+28%8.212-17%7.720-11%
Return On Assets---0.079-0.103+31%-0.140+77%-0.142+79%-0.221+179%
Return On Equity---0.086-0.113+32%-0.156+82%-0.157+83%-0.357+316%
Total Gains Per Share---0.001-100%-0.0190%0.006-100%0.006-100%
Usd Book Value--13162995.62112095441.244+9%13998393.333-6%15733919.391-16%10431484.536+26%
Usd Book Value Change Per Share---0.001-100%-0.0130%0.004-100%0.004-100%
Usd Book Value Per Share--0.1180.108+9%0.126-6%0.141-16%0.094+26%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.010-0.012+18%-0.013+31%-0.019+93%-0.013+32%
Usd Free Cash Flow---928159.053-877559.803-5%-1805588.288+95%-1231843.069+33%-891625.646-4%
Usd Free Cash Flow Per Share---0.008-0.008-5%-0.016+95%-0.011+33%-0.008-4%
Usd Free Cash Flow To Equity Per Share--0.0100.001+1189%-0.017+275%-0.001+107%0.000+2269%
Usd Market Cap33053256.990-24%41132942.03243979194.717-6%46366374.389-11%54137562.366-24%34368501.174+20%
Usd Price Per Share0.296-24%0.3690.394-6%0.416-11%0.485-24%0.308+20%
Usd Profit---1128409.017-1336658.172+18%-2215178.378+96%-2320664.595+106%-1585378.174+40%
Usd Revenue--449002.526273415.979+64%193265.182+132%190796.288+135%136260.450+230%
Usd Total Gains Per Share---0.001-100%-0.0130%0.004-100%0.004-100%
 EOD+2 -5MRQTTM+21 -12YOY+22 -75Y+19 -1410Y+21 -12

3.3 Fundamental Score

Let's check the fundamental score of Inoviq Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.323
Price to Book Ratio (EOD)Between0-12.511
Net Profit Margin (MRQ)Greater than0-2.513
Operating Margin (MRQ)Greater than0-2.591
Quick Ratio (MRQ)Greater than16.846
Current Ratio (MRQ)Greater than17.074
Debt to Asset Ratio (MRQ)Less than10.079
Debt to Equity Ratio (MRQ)Less than10.086
Return on Equity (MRQ)Greater than0.15-0.086
Return on Assets (MRQ)Greater than0.05-0.079
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Inoviq Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.460
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Inoviq Ltd

INOVIQ Ltd engages in the developing and commercializing of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. Its cancer diagnostic pipeline includes internal and partnered diagnostic tests for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.

Fundamental data was last updated by Penke on 2024-11-01 23:41:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Inoviq earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Inoviq to the Diagnostics & Research industry mean.
  • A Net Profit Margin of -251.3% means that $-2.51 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Inoviq Ltd:

  • The MRQ is -251.3%. The company is making a huge loss. -2
  • The TTM is -915.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-251.3%TTM-915.2%+663.9%
TTM-915.2%YOY-2,121.9%+1,206.6%
TTM-915.2%5Y-2,011.0%+1,095.7%
5Y-2,011.0%10Y-2,600.9%+589.9%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-251.3%-2.6%-248.7%
TTM-915.2%-7.1%-908.1%
YOY-2,121.9%-5.1%-2,116.8%
5Y-2,011.0%-2.7%-2,008.3%
10Y-2,600.9%-0.3%-2,600.6%
4.3.1.2. Return on Assets

Shows how efficient Inoviq is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Inoviq to the Diagnostics & Research industry mean.
  • -7.9% Return on Assets means that Inoviq generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Inoviq Ltd:

  • The MRQ is -7.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.9%TTM-10.3%+2.4%
TTM-10.3%YOY-14.0%+3.6%
TTM-10.3%5Y-14.2%+3.8%
5Y-14.2%10Y-22.1%+7.9%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.9%-0.9%-7.0%
TTM-10.3%-1.3%-9.0%
YOY-14.0%-1.0%-13.0%
5Y-14.2%-0.3%-13.9%
10Y-22.1%-0.5%-21.6%
4.3.1.3. Return on Equity

Shows how efficient Inoviq is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Inoviq to the Diagnostics & Research industry mean.
  • -8.6% Return on Equity means Inoviq generated $-0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Inoviq Ltd:

  • The MRQ is -8.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.6%TTM-11.3%+2.7%
TTM-11.3%YOY-15.6%+4.3%
TTM-11.3%5Y-15.7%+4.4%
5Y-15.7%10Y-35.7%+20.0%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.6%-0.5%-8.1%
TTM-11.3%-0.7%-10.6%
YOY-15.6%-0.2%-15.4%
5Y-15.7%-1.0%-14.7%
10Y-35.7%-1.5%-34.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Inoviq Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Inoviq is operating .

  • Measures how much profit Inoviq makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Inoviq to the Diagnostics & Research industry mean.
  • An Operating Margin of -259.1% means the company generated $-2.59  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Inoviq Ltd:

  • The MRQ is -259.1%. The company is operating very inefficient. -2
  • The TTM is -750.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-259.1%TTM-750.1%+491.0%
TTM-750.1%YOY-1,575.6%+825.4%
TTM-750.1%5Y-1,509.0%+758.8%
5Y-1,509.0%10Y-2,258.5%+749.5%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-259.1%-16.8%-242.3%
TTM-750.1%-14.1%-736.0%
YOY-1,575.6%1.8%-1,577.4%
5Y-1,509.0%2.0%-1,511.0%
10Y-2,258.5%5.0%-2,263.5%
4.3.2.2. Operating Ratio

Measures how efficient Inoviq is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of 5.20 means that the operating costs are $5.20 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Inoviq Ltd:

  • The MRQ is 5.202. The company is inefficient in keeping operating costs low. -1
  • The TTM is 12.010. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ5.202TTM12.010-6.808
TTM12.010YOY24.407-12.397
TTM12.0105Y20.676-8.666
5Y20.67610Y26.830-6.154
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ5.2021.314+3.888
TTM12.0101.283+10.727
YOY24.4071.268+23.139
5Y20.6761.239+19.437
10Y26.8301.192+25.638
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Inoviq Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Inoviq is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 7.07 means the company has $7.07 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Inoviq Ltd:

  • The MRQ is 7.074. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.009. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.074TTM6.009+1.065
TTM6.009YOY5.738+0.271
TTM6.0095Y8.513-2.504
5Y8.51310Y7.920+0.594
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0742.015+5.059
TTM6.0092.134+3.875
YOY5.7382.558+3.180
5Y8.5132.748+5.765
10Y7.9203.230+4.690
4.4.3.2. Quick Ratio

Measures if Inoviq is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Inoviq to the Diagnostics & Research industry mean.
  • A Quick Ratio of 6.85 means the company can pay off $6.85 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Inoviq Ltd:

  • The MRQ is 6.846. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.577. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.846TTM5.577+1.269
TTM5.577YOY5.358+0.220
TTM5.5775Y8.212-2.634
5Y8.21210Y7.720+0.491
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ6.8461.195+5.651
TTM5.5771.275+4.302
YOY5.3581.694+3.664
5Y8.2122.141+6.071
10Y7.7202.443+5.277
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Inoviq Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Inoviq assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Inoviq to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 0.08 means that Inoviq assets are financed with 7.9% credit (debt) and the remaining percentage (100% - 7.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Inoviq Ltd:

  • The MRQ is 0.079. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.085. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.079TTM0.085-0.006
TTM0.085YOY0.103-0.019
TTM0.0855Y0.090-0.006
5Y0.09010Y0.149-0.058
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0790.440-0.361
TTM0.0850.438-0.353
YOY0.1030.359-0.256
5Y0.0900.417-0.327
10Y0.1490.443-0.294
4.5.4.2. Debt to Equity Ratio

Measures if Inoviq is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Inoviq to the Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 8.6% means that company has $0.09 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Inoviq Ltd:

  • The MRQ is 0.086. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.093. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.086TTM0.093-0.007
TTM0.093YOY0.116-0.023
TTM0.0935Y0.100-0.008
5Y0.10010Y0.241-0.140
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0860.642-0.556
TTM0.0930.669-0.576
YOY0.1160.517-0.401
5Y0.1000.656-0.556
10Y0.2410.730-0.489
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Inoviq generates.

  • Above 15 is considered overpriced but always compare Inoviq to the Diagnostics & Research industry mean.
  • A PE ratio of -9.11 means the investor is paying $-9.11 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Inoviq Ltd:

  • The EOD is -7.323. Based on the earnings, the company is expensive. -2
  • The MRQ is -9.113. Based on the earnings, the company is expensive. -2
  • The TTM is -8.738. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.323MRQ-9.113+1.790
MRQ-9.113TTM-8.738-0.375
TTM-8.738YOY-8.504-0.234
TTM-8.7385Y-7.470-1.268
5Y-7.47010Y-5.030-2.441
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-7.323-0.392-6.931
MRQ-9.113-0.727-8.386
TTM-8.738-0.715-8.023
YOY-8.504-0.081-8.423
5Y-7.4702.156-9.626
10Y-5.0303.438-8.468
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Inoviq Ltd:

  • The EOD is -8.903. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.079. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -13.237. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.903MRQ-11.079+2.176
MRQ-11.079TTM-13.237+2.157
TTM-13.237YOY-6.824-6.413
TTM-13.2375Y-12.861-0.376
5Y-12.86110Y-8.455-4.405
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-8.903-0.601-8.302
MRQ-11.079-1.077-10.002
TTM-13.237-1.310-11.927
YOY-6.824-2.928-3.896
5Y-12.861-2.255-10.606
10Y-8.455-2.805-5.650
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Inoviq is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of 3.12 means the investor is paying $3.12 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Inoviq Ltd:

  • The EOD is 2.511. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.125. Based on the equity, the company is fair priced.
  • The TTM is 3.672. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.511MRQ3.125-0.614
MRQ3.125TTM3.672-0.547
TTM3.672YOY3.351+0.321
TTM3.6725Y3.151+0.521
5Y3.15110Y2.921+0.230
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD2.5112.278+0.233
MRQ3.1252.139+0.986
TTM3.6722.222+1.450
YOY3.3512.268+1.083
5Y3.1513.746-0.595
10Y2.9214.266-1.345
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. All numbers in thousands.

Summary
Total Assets21,706
Total Liabilities1,719
Total Stockholder Equity19,986
 As reported
Total Liabilities 1,719
Total Stockholder Equity+ 19,986
Total Assets = 21,706

Assets

Total Assets21,706
Total Current Assets10,857
Long-term Assets10,848
Total Current Assets
Cash And Cash Equivalents 9,233
Net Receivables 1,274
Inventory 18
Total Current Assets  (as reported)10,857
Total Current Assets  (calculated)10,525
+/- 332
Long-term Assets
Property Plant Equipment 1,146
Intangible Assets 9,702
Other Assets 0
Long-term Assets  (as reported)10,848
Long-term Assets  (calculated)10,848
+/- 0

Liabilities & Shareholders' Equity

Total Current Liabilities1,535
Long-term Liabilities185
Total Stockholder Equity19,986
Total Current Liabilities
Short-term Debt 373
Accounts payable 626
Other Current Liabilities 241
Total Current Liabilities  (as reported)1,535
Total Current Liabilities  (calculated)1,241
+/- 294
Long-term Liabilities
Long-term Liabilities  (as reported)185
Long-term Liabilities  (calculated)0
+/- 185
Total Stockholder Equity
Common Stock75,126
Retained Earnings -56,916
Accumulated Other Comprehensive Income 1,776
Total Stockholder Equity (as reported)19,986
Total Stockholder Equity (calculated)19,986
+/-0
Other
Cash and Short Term Investments 9,233
Common Stock Shares Outstanding 92,830
Current Deferred Revenue294
Liabilities and Stockholders Equity 21,706
Net Debt -8,698
Net Working Capital 9,323
Short Long Term Debt Total 535



6.2. Balance Sheets Structured

All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-301999-06-301997-06-30
> Total Assets 
11,326
9,466
2,872
2,663
3,504
17,439
12,597
2,785
6,133
19,964
19,595
26,848
16,292
4,226
2,824
1,848
2,088
2,088
727
727
1,239
1,239
1,453
1,453
3,750
3,750
7,627
7,627
8,735
8,735
7,374
7,374
41,064
41,064
33,522
32,939
47,205
47,205
42,461
30,779
25,984
25,984
21,509
21,509
18,406
18,406
21,706
21,706
21,70621,70618,40618,40621,50921,50925,98425,98430,77942,46147,20547,20532,93933,52241,06441,0647,3747,3748,7358,7357,6277,6273,7503,7501,4531,4531,2391,2397277272,0882,0881,8482,8244,22616,29226,84819,59519,9646,1332,78512,59717,4393,5042,6632,8729,46611,326
   > Total Current Assets 
2,306
926
1,430
1,236
858
3,224
366
2,777
2,487
15,775
7,335
1,800
991
255
59
1,735
2,028
2,028
699
699
1,210
1,210
1,453
1,453
3,750
3,750
7,627
7,627
8,735
8,735
7,374
7,374
7,867
7,867
5,649
5,649
20,258
20,258
17,467
17,467
13,331
13,331
9,403
9,403
6,936
6,936
10,857
10,857
10,85710,8576,9366,9369,4039,40313,33113,33117,46717,46720,25820,2585,6495,6497,8677,8677,3747,3748,7358,7357,6277,6273,7503,7501,4531,4531,2101,2106996992,0282,0281,735592559911,8007,33515,7752,4872,7773663,2248581,2361,4309262,306
       Cash And Cash Equivalents 
2,143
126
669
1,040
359
2,853
128
512
1,631
15,284
1,598
961
565
75
30
1,729
1,932
1,932
650
650
1,210
1,210
1,446
1,446
3,713
3,713
7,557
7,557
8,699
8,699
7,327
7,327
7,258
7,258
4,999
4,999
18,561
18,561
15,395
15,395
11,925
11,925
7,813
7,813
5,974
5,974
9,233
9,233
9,2339,2335,9745,9747,8137,81311,92511,92515,39515,39518,56118,5614,9994,9997,2587,2587,3277,3278,6998,6997,5577,5573,7133,7131,4461,4461,2101,2106506501,9321,9321,72930755659611,59815,2841,6315121282,8533591,0406691262,143
       Short-term Investments 
153
22
632
119
6
3
0
0
727
478
359
812
172
132
4
4
12
12
17
17
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000001717121244132172812359478727003611963222153
       Net Receivables 
10
334
128
75
265
238
64
9
100
11
5,369
11
20
22
25
2
84
84
0
32
0
0
0
3
1
1
0
61
0
36
0
21
122
122
169
220
1,201
1,201
1,706
1,706
1,080
1,080
73
1,193
641
641
27
1,274
1,274276416411,193731,0801,0801,7061,7061,2011,20122016912212221036061011300032084842252220115,369111009642382657512833410
       Other Current Assets 
0
0
0
0
225
0
0
0
0
0
0
0
1
0
0
0
12
12
49
49
0
0
7
7
36
36
70
9
36
36
47
26
453
453
434
383
440
440
353
353
305
305
1,501
0
306
306
1,248
1,248
1,2481,24830630601,501305305353353440440383434453453264736369703636770049491212000100000002250000
   > Long-term Assets 
9,020
8,540
1,442
1,428
2,646
14,216
12,231
8
3,646
4,189
12,261
25,048
15,301
3,971
2,766
113
60
60
28
28
28
28
0
0
0
0
0
0
0
58,714
0
0
33,197
33,197
27,873
27,290
26,947
26,947
24,994
13,313
12,652
12,652
12,105
12,105
11,470
11,470
10,848
10,848
10,84810,84811,47011,47012,10512,10512,65212,65213,31324,99426,94726,94727,29027,87333,19733,1970058,71400000002828282860601132,7663,97115,30125,04812,2614,1893,646812,23114,2162,6461,4281,4428,5409,020
       Property Plant Equipment 
2,890
702
1,432
1,419
2,636
9,605
12,231
8
14
12
7
3
5
3
1
0
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,820
1,820
1,727
1,727
1,619
1,619
1,647
1,647
1,527
1,527
1,454
1,454
1,292
1,292
1,146
1,146
1,1461,1461,2921,2921,4541,4541,5271,5271,6471,6471,6191,6191,7271,7271,8201,82000000000000000440135371214812,2319,6052,6361,4191,4327022,890
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,338
0
0
27,338
27,338
11,031
11,031
11,031
11,031
11,031
11,031
0
0
0
0
0
0
0
0
0000000011,03111,03111,03111,03111,03111,03127,33827,3380027,33800000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,376
0
0
4,039
4,039
15,115
25,563
14,298
14,298
12,316
10,652
11,126
11,126
10,652
10,652
10,178
10,178
9,702
9,702
9,7029,70210,17810,17810,65210,65211,12611,12610,65212,31614,29814,29825,56315,1154,0394,0390031,37600000000000000000000000000000
       Long-term Assets Other 
173
0
11
9
10
4,260
0
0
0
0
0
0
0
0
0
0
-60
-60
-28
0
-28
-28
0
0
0
0
0
0
0
-58,714
0
0
0
0
-27,873
0
-26,947
14,202
-13,313
1,014
-12,652
-12,652
-12,105
0
0
10,178
0
9,702
9,702010,17800-12,105-12,652-12,6521,014-13,31314,202-26,9470-27,8730000-58,7140000000-28-280-28-60-6000000000004,260109110173
> Total Liabilities 
882
373
544
180
723
557
1,554
741
466
937
706
246
1,187
1,309
1,936
90
417
417
459
469
320
320
301
323
370
370
463
492
526
558
876
899
2,361
2,361
4,465
5,098
3,511
3,511
2,487
2,487
3,090
3,090
1,893
1,893
1,661
1,661
1,719
1,719
1,7191,7191,6611,6611,8931,8933,0903,0902,4872,4873,5113,5115,0984,4652,3612,361899876558526492463370370323301320320469459417417901,9361,3091,1872467069374667411,554557723180544373882
   > Total Current Liabilities 
320
220
356
109
723
557
1,554
741
466
937
706
246
1,187
1,309
1,936
90
417
417
459
469
320
320
301
301
370
370
463
463
526
526
876
876
1,246
1,246
1,459
1,459
1,213
1,213
1,796
1,796
2,525
2,525
1,518
1,518
1,403
1,403
1,535
1,535
1,5351,5351,4031,4031,5181,5182,5252,5251,7961,7961,2131,2131,4591,4591,2461,246876876526526463463370370301301320320469459417417901,9361,3091,1872467069374667411,554557723109356220320
       Short-term Debt 
0
5
0
0
0
0
706
490
0
0
0
0
1,000
1,156
1,821
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
342
0
347
0
352
357
357
0
362
0
0
0
327
0
373
37303270003620357357352034703420000000000000000001,8211,1561,0000000490706000050
       Accounts payable 
74
203
150
67
657
454
718
87
419
266
3
0
0
0
0
0
393
393
423
423
257
257
238
238
353
353
428
428
470
470
799
799
605
605
605
605
483
483
1,020
1,046
1,925
1,925
467
467
746
746
626
626
6266267467464674671,9251,9251,0461,020483483605605605605799799470470428428353353238238257257423423393393000003266419877184546576715020374
       Other Current Liabilities 
246
12
206
43
65
103
130
164
48
671
702
0
187
153
115
0
24
24
36
46
63
63
62
62
17
17
35
35
56
56
77
77
641
299
854
508
730
378
419
392
599
237
1,051
0
657
330
908
241
24190833065701,051237599392419378730508854299641777756563535171762626363463624240115153187070267148164130103654320612246
   > Long-term Liabilities 
563
153
188
70
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22
0
0
0
29
0
32
0
23
1,115
1,115
3,006
3,639
2,298
2,298
691
691
565
565
376
376
258
258
185
185
1851852582583763765655656916912,2982,2983,6393,0061,1151,1152303202900022000000000000000000070188153563
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,072
0
918
0
783
0
642
0
492
0
368
0
0
0
0
0000368049206420783091801,072000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
73
73
7
7
0
0
0
0
00007773730000000000000000000000000000000000000000
> Total Stockholder Equity
10,444
9,093
2,311
2,477
2,770
16,872
11,043
2,044
5,667
19,027
18,890
26,602
15,106
2,917
888
1,758
1,670
1,670
258
258
918
918
1,130
1,130
3,360
3,360
7,135
7,135
8,178
8,178
6,475
6,475
38,703
38,703
29,057
27,840
43,694
43,694
39,974
28,293
22,894
22,894
19,615
19,615
16,744
16,744
19,986
19,986
19,98619,98616,74416,74419,61519,61522,89422,89428,29339,97443,69443,69427,84029,05738,70338,7036,4756,4758,1788,1787,1357,1353,3603,3601,1301,1309189182582581,6701,6701,7588882,91715,10626,60218,89019,0275,6672,04411,04316,8722,7702,4772,3119,09310,444
   Common Stock
8,502
13,677
16,054
17,562
18,986
36,214
39,367
41,346
41,346
50,552
50,552
60,040
60,040
60,040
60,040
61,538
6,620
6,620
6,645
6,645
8,070
8,070
9,298
9,298
12,393
12,393
16,980
16,980
19,287
19,287
19,287
19,287
54,217
54,217
51,832
51,832
69,081
69,081
69,053
69,053
69,053
69,053
69,053
69,053
69,053
69,053
75,126
75,126
75,12675,12669,05369,05369,05369,05369,05369,05369,05369,05369,08169,08151,83251,83254,21754,21719,28719,28719,28719,28716,98016,98012,39312,3939,2989,2988,0708,0706,6456,6456,6206,62061,53860,04060,04060,04060,04050,55250,55241,34641,34639,36736,21418,98617,56216,05413,6778,502
   Retained Earnings -56,916-56,916-53,489-53,489-51,073-51,073-47,754-47,754-41,858-30,176-26,573-26,573-25,171-23,955-16,078-16,078-12,828-12,828-11,132-11,132-9,575-9,575-8,737-8,737-7,857-7,857-6,813-6,813-6,040-6,040-4,660-4,660-59,826-56,842-56,083-45,568-35,120-33,561-31,955-35,719-40,892-29,805-19,342-16,216-15,085-13,743-3,997-1,750
   Accumulated Other Comprehensive Income 
4,168
-586
0
0
0
0
1,482
1,590
41
430
1,899
1,683
634
-1,039
-2,309
46
-290
-290
-348
-348
-338
-338
-311
-311
-296
-296
-271
-271
23
23
16
16
564
564
1,179
1,179
1,186
1,186
1,097
1,097
1,594
1,594
1,635
0
1,180
1,180
1,776
1,776
1,7761,7761,1801,18001,6351,5941,5941,0971,0971,1861,1861,1791,17956456416162323-271-271-296-296-311-311-338-338-348-348-290-29046-2,309-1,0396341,6831,899430411,5901,4820000-5864,168
   Capital Surplus 000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
-476
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-695
0
0
0
0
0
0
0
-542
0
0
0
0
-63
564
0
1,179
-23
1,186
35
0
-52
0
1,594
0
1,635
0
0
0
0
00001,63501,5940-520351,186-231,1790564-630000-5420000000-69500000000000000000-476



6.3. Balance Sheets

All numbers in thousands.




6.4. Cash Flows

All numbers in thousands.